Results 271 to 280 of about 54,096 (328)

Editorial: Allogenic hematopoietic cell transplant in hematological malignancies: controversies and perspective. [PDF]

Front Oncol
Leotta S, Giammarco S, Mariotti J.
europepmc   +1 more source

Development of a Rapid LC-MS/MS Method and Its Application for the Pharmacokinetic Analysis of Pacritinib in Rats. [PDF]

J Mass Spectrom
Wu YM, Zheng K, Huang LY, Ni JH, Tang PF, Qian JC, Xiao ZX, Li YL.   +7 more
europepmc   +1 more source

Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design. [PDF]

Future Oncol
Mascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, Chai Y, Kye S, Method M, Harrison C, SENTRY investigators.   +10 more
europepmc   +1 more source

Research trends in essential thrombocythemia from 2001 to 2024: a bibliometric analysis. [PDF]

Discov Oncol
Pan Y, Chen L, Jiang Q, Chen D, Wu Y, Hou L, Lang H, Yan J.   +7 more
europepmc   +1 more source

A Retrospective Study of 19 Cases of Canine Myelofibrosis

, 2002
Douglas J. Weiss, Stephanie A. Smith
openalex   +1 more source

How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024. [PDF]

Ann Hematol
Griesshammer M, Al-Ali HK, Eckardt JN, Fiegl M, Göthert J, Jentsch-Ullrich K, Koschmieder S, Kvasnicka HM, Reiter A, Schmidt B, Heidel FH.   +10 more
europepmc   +1 more source

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study

, 2002
David P. Steensma, Ruben A. Mesa, Chin‐Yang Li, Leigh A. Gray, Ayalew Tefferi   +4 more
openalex   +1 more source

Safety and Efficacy of Busulphan Based on Dosing Patterns in the Real-World Management of Myeloproliferative Neoplasms. [PDF]

EJHaem
Mahdi A, Rampotas A, Roberts P, Stokes J, Mahdi E, Witherall R, Mannari D, Ibrahim N, Naylor G, Garg M, Manjra I, Glancy P, Katis G, Bhagat S, Coppell J, McGregor A, Frewin R, Butt NM.   +17 more
europepmc   +1 more source

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling. [PDF]

Nat Commun
Gorantla SP, Rassner M, Crossley KA, Müller TA, Poggio T, Khaja Saleem S, Kleinfelder H, Gambheer SMM, Endres C, Schaberg S, Schmidt D, Prince G, Gonzalez-Menendez I, Bentrop D, Trittler R, Rylova S, Pfeifer D, Andrieux G, Quintanilla-Martinez L, Illert AL, von Bubnoff N, Zeiser R, Duyster J.   +22 more
europepmc   +1 more source

¹⁸F-FDG PET/CT findings in a mucosa-associated lymphoid tissue lymphoma patient coexisting with primary myelofibrosis. [PDF]

Am J Nucl Med Mol Imaging
Han Y, Wu R, Zhang Y, Zhang X, Gao Z.
europepmc   +1 more source